Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle loss may predict CAR-T outcomes in lymphoma

NCT ID NCT06156774

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works or causes more side effects. The goal is to learn whether simple muscle assessments can help predict outcomes, but this study does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥ 18 years old). * Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug * Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART * Written informed consent voluntarily provided Exclusion Criteria: * Patients not fulfilling the eligibility criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-Hodgkin lymphoma, B-cell are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma, B-cell

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia

    RECRUITING

    Palermo, Italy

  • A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia

    RECRUITING

    Alessandria, Italy

  • A.O.U. Citta della Salute e della Scienza di Torino - S.C. Ematologia

    RECRUITING

    Torino, Italy

  • AOU Integrata di Verona - U.O. Ematologia

    RECRUITING

    Verona, Italy

  • AOU Ospedali Riuniti - Clinica di Ematologia

    RECRUITING

    Ancona, Italy

  • AOU Pisana - U.O. Ematologia

    NOT_YET_RECRUITING

    Pisa, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

    RECRUITING

    Milan, Italy

  • ASST Spedali Civili di Brescia - S.C. Ematologia

    RECRUITING

    Brescia, Italy

  • Azienda Ospedaliera S .Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

    RECRUITING

    Avellino, Italy

  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

    RECRUITING

    Florence, Italy

  • Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - Clinica di Ematologia

    RECRUITING

    Udine, Italy

  • Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

    RECRUITING

    Reggio Emilia, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia

    RECRUITING

    Milan, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica S. Cuore - Ematologia

    RECRUITING

    Roma, Italy

  • IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati

    RECRUITING

    Aviano, Italy

  • Istituto Scientifico San Raffaele - Unità Linfomi - Dipartimento Oncoematologia

    RECRUITING

    Milan, Italy

  • Ospedale Guglielmo da Saliceto - U.O. Ematologia

    RECRUITING

    Piacenza, Italy

  • Ospedale S. Maria della Misericordia - Ematologia

    RECRUITING

    Perugia, Italy

  • Ospedale di Castelfranco Veneto - Oncoematologia IOV

    RECRUITING

    Castelfranco Veneto, Italy

  • Policlinico Umberto I - Università "La Sapienza" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione

    RECRUITING

    Roma, Italy

  • ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

    RECRUITING

    Vicenza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.